Does Vyvanse (lisdexamfetamine) cause hypertension?

Yes, Vyvanse (lisdexamfetamine) causes hypertension and increases blood pressure.

Vyvanse, like all amphetamines, directly increases blood pressure and heart rate through its sympathomimetic effects, and this is a well-documented, dose-dependent cardiovascular effect that requires monitoring throughout treatment. 1

Mechanism and Magnitude of Blood Pressure Elevation

Vyvanse and other CNS stimulants cause measurable increases in blood pressure through increased sympathetic nervous system activity. According to the FDA label, CNS stimulants cause a mean increase of approximately 2-4 mmHg in systolic blood pressure and 3-6 bpm in heart rate, though some patients experience larger increases 1. A comprehensive Cochrane review of 56 randomized controlled trials involving over 10,000 participants confirmed that amphetamines (including lisdexamfetamine) increase systolic blood pressure by 1.93 mmHg and diastolic blood pressure by 1.84 mmHg, with high-certainty evidence 2.

Clinical Guidelines on Amphetamines and Hypertension

Multiple authoritative hypertension guidelines explicitly list amphetamines as medications that cause elevated blood pressure:

• The 2017 ACC/AHA Hypertension Guidelines specifically identify amphetamines (including amphetamine, methylphenidate, dexmethylphenidate, and dextroamphetamine) as agents that may cause elevated BP 3, 4, 5, 4. The recommended management strategy is to "discontinue or decrease dose" and "consider behavioral therapies for ADHD" 3, 4.

• The 2020 International Society of Hypertension Guidelines also list sympathomimetics including amphetamines as drug exacerbators and inducers of hypertension 6.

• These guidelines emphasize that amphetamines are contraindicated in uncontrolled hypertension and should be avoided in severe hypertension 3, 4.

FDA-Mandated Warnings and Monitoring Requirements

The FDA label for Vyvanse contains explicit warnings about cardiovascular effects:

• Section 5.3 "Increased Blood Pressure and Heart Rate" states: "CNS stimulants cause an increase in blood pressure and heart rate. Monitor all VYVANSE-treated patients for potential tachycardia and hypertension" 1.

• Vyvanse is contraindicated in patients taking MAOIs due to risk of hypertensive crisis 1.

• The label documents that in adult clinical trials, hypertension was a reason for discontinuation in 1% of patients (4/358), which was twice the rate of placebo 1.

Long-Term Cardiovascular Risk Data

Recent large-scale population studies reveal concerning long-term patterns:

• A 2024 Swedish case-control study of 278,027 individuals with ADHD found that longer cumulative duration of ADHD medication use was associated with progressively increased cardiovascular disease risk. Specifically, use for 3-5 years showed an adjusted odds ratio of 1.72 for hypertension, and use >5 years showed an AOR of 1.80 for hypertension 7. Each additional year of ADHD medication use was associated with a 4% increased CVD risk, with the largest increase occurring in the first 3 years 7.

• The Cochrane review found that participants taking amphetamines were 2.69 times more likely to withdraw from studies due to adverse effects compared to placebo, with an absolute risk increase of 4.3% 2.

Clinical Management Algorithm

For patients requiring Vyvanse:

1. Baseline assessment: Measure blood pressure and heart rate before initiating treatment. Screen for pre-existing cardiovascular disease, hypertension, or structural cardiac abnormalities 1.

2. Contraindications: Do NOT prescribe Vyvanse in patients with:

   • Uncontrolled hypertension
   • Serious cardiac disease, structural cardiac abnormalities, or cardiomyopathy
   • Current MAOI use or within 14 days of stopping MAOIs 1

3. Monitoring during treatment:

   • Check blood pressure and heart rate at each follow-up visit
   • Monitor more frequently during dose titration
   • The FDA label explicitly requires monitoring "all VYVANSE-treated patients for potential tachycardia and hypertension" 1

4. If hypertension develops:

   • First-line: Reduce Vyvanse dose or discontinue 3, 4
   • Consider behavioral therapies for ADHD as alternatives 3, 4
   • If Vyvanse must be continued, initiate or intensify antihypertensive therapy while continuing close BP monitoring

5. Long-term considerations: Given the dose-dependent and duration-dependent cardiovascular risks, regularly reassess the necessity of continued stimulant therapy, especially after 2-3 years of use when cardiovascular risk appears to increase more substantially 7.

Important Caveats

• The blood pressure increases are sustained effects, not just acute responses—subgroup analysis of studies ≥8 weeks duration showed similar elevations 2.

• Individual responses vary considerably; while mean increases are modest (2-4 mmHg), some patients experience much larger increases 1.

• The cardiovascular effects are class effects of all amphetamines, not unique to Vyvanse. However, one comparative study found no increased risk of major cardiovascular events with lisdexamfetamine compared to other ADHD medications in adults 8.

• In patients with pre-existing mild hypertension, a study found that 10% of adults on active ADHD medications developed new-onset hypertension (BP ≥140/90) during treatment 9.